Welcome to our dedicated page for DiaMedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
DiaMedica Therapeutics Inc. Schedule 13G/A shows that Trill AB and its board member Jan Stahlberg report beneficial ownership of 7,764,465 common shares, representing 15.02% of DiaMedica's outstanding common stock (based on 51,688,913 shares outstanding as of August 8, 2025). The filing identifies Trill AB as the record holder and Mr. Stahlberg as a beneficial owner and board member. The reported holdings reflect shared voting and shared dispositive power of 7,764,465 shares for each reporting person, with no sole voting or dispositive power. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
DiaMedica Therapeutics Inc. (DMAC) received a Schedule 13G disclosing that Leon G. Cooperman may be deemed the beneficial owner of 3,110,220 Voting Common Shares, representing approximately 6.0% of the company's outstanding common shares. That total comprises 2,450,000 shares held directly by Mr. Cooperman and 660,220 shares held directly by The Leon and Toby Cooperman Foundation.
The filing states the ownership percentage is calculated using 51,688,913 shares outstanding as of August 8, 2025, per the issuer's quarterly report. The statement affirms the shares were not acquired to change or influence control of the issuer and lists Edward Levy signing as attorney-in-fact on behalf of Mr. Cooperman.
DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell, from time to time, up to $100.0 million of its common shares through an at-the-market program. TD Cowen will act as sales agent and may receive compensation of up to 3.0% of gross proceeds. Sales are to be made under the company’s Form S-3 shelf registration and may not occur until that registration is declared effective. The agreement contains customary representations, indemnities, and incorporated legal opinions from Pushor Mitchell and Alston & Bird.
DiaMedica Therapeutics filed a shelf registration to offer up to $100,000,000 of common shares, warrants and units and a sales agreement permitting up to $100,000,000 of common shares to be sold from time to time under an agreement with TD Securities (USA) LLC. The company’s lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of KLK1 being developed for preeclampsia (PE) and acute ischemic stroke (AIS); DM199 holds Fast Track designation for AIS and avoids human/animal tissue sourcing.
Clinical progress includes an interim Phase 2 investigator-sponsored PE result (N=28) reporting safe, well-tolerated profiles, rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion and no evidence of placental transfer. DiaMedica plans a U.S. IND submission in the second half of 2025. The Phase 2/3 ReMEDy2 AIS trial is adaptive (target ~300, maximum up to 728 after interim analysis of 200) but is experiencing slower-than-expected site activation and enrollment; the company is expanding internal capabilities and global site filings to mitigate delays.
DiaMedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company developing DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). Interim results from the investigator-sponsored Phase 2 PE Part 1a (N=28) showed DM199 appeared safe and well-tolerated, with no evidence of placental transfer and rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion. Preparations are underway to start Part 1b.
The ReMEDy2 Phase 2/3 adaptive AIS trial is ongoing but experiencing slower-than-expected site activations and enrollment due to staffing shortages, protocol criteria, prior hypotension events, and site retention of patients; the company is expanding its internal clinical team and global site footprint to mitigate delays. The adaptive design targets ~300 participants (interim analysis at 200) with a potential final sample up to 728.
Financially, DiaMedica reported a six-month net loss of $15.4 million, cash and marketable securities of $30.0 million and an accumulated deficit of $155.4 million as of June 30, 2025. In July 2025 the company completed a private placement raising net proceeds of $29.9 million, which management states, together with existing resources, should fund operations for at least the next 12 months. R&D and G&A expenses increased year-over-year as clinical activity expanded.
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended June 30, 2025 and provided a business update via a press release attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is furnished and incorporated by reference into Item 2.02, and expressly notes the information is not "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically referenced. The company’s voting common shares trade on The Nasdaq Stock Market under the symbol DMAC. The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page); the 8-K text itself contains no financial tables or line-item results, so readers must consult Exhibit 99.1 for detailed Q2 2025 figures and commentary.
Amendment No. 2 to Schedule 13G, filed 30 Jul 2025, shows Swedish investment vehicle Trill AB and its beneficial owner Jan Stahlberg now hold 6,764,465 DiaMedica Therapeutics Inc. (DMAC) common shares. The position equals 13.14 % of the company’s outstanding stock, calculated against 42.88 M shares outstanding on 9 May 2025 plus 8.61 M shares expected from a July 2025 private placement. All shares carry shared voting and dispositive power; neither Trill AB nor Stahlberg retains sole authority. The certification states the investment is passive and not intended to influence control. No additional transactions, board actions, or financing terms are disclosed.